Toggle navigation
Home
Search
Services
Blog
Contact
About
Production and Testing of rPA Vaccine-26630053
Vaxgen Inc.
Search grants from Vaxgen Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Publications
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Highly specific, amplification-free, single-molecule counting of rare methylated DNA cancer biomarkers
NOS1AP and Capon Associated Impaired Healing in Those with Diabetic Foot Ulcers
Treatment of glioblastoma using chain-like nanoparticles
SSRIs and Self-harm in Borderline Personality Disorder
Transmembrane Domains in Membrane Fusion
Recently added grants:
Project 3 - Genomics of Secondary AML Progression.
Project 4 - Genomics of TP53-mutant AML.
Core D: Administration Core.
Core A - Clinical Database.
Core B - Specimen Database.
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research and Development Contracts (N01)
Project #
N01AI030053-005
Application #
6994669
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2004
Total Cost
Indirect Cost
Institution
Name
Vaxgen Inc.
Department
Type
DUNS #
City
State
Country
Zip Code
Related projects
NIH 2006
N01 AI
Production and Testing of Anthrax Recombinant Protective Antigen /Rpa/-266030053
/ Vaxgen Inc.
NIH 2005
N01 AI
Production and Testing of Anthrax Recombinant Protective Antigen /Rpa/-266030053
/ Vaxgen Inc.
NIH 2004
N01 AI
Production and Testing of rPA Vaccine-26630053
/ Vaxgen Inc.
NIH 2003
N01 AI
Production and Testing of Anthrax Recombinant Protective Antigen Vacci-
/ Vaxgen Inc.
Publications
Omland, Kristian S; Brys, April; Lansky, David et al.
(2008)
Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple species.
Clin Vaccine Immunol 15:946-53
Comments
Be the first to comment on this grant